Bio IT World Expo 2016  
Bio IT World Expo 2016
Archived Content

Track 9: Drug Discovery Informatics 

Track 9 will showcase collaborations that address the challenge of information integration and standardization for drug discovery, recent researches on pharmacogenomics through the integration of clinical genomics information system with electronic medical records, in order to advance human health through genomics research. Novel informatics approaches in drug discovery, in areas such as tissue-specific mutations and epigenetics will also be examined.

Final Agenda

Download Brochure | Pre-Conference Workshops 


7:00 am Workshop Registration and Morning Coffee

8:00 Pre-Conference Workshops*

Quality Practices for R&D Informatics Platform Selection and Solution Development

Advancing the Use of EHR/EMR for Clinical Research and Drug Development: Breaking Down Barriers & Building Up Bridges

*Separate Registration Required

2:00 - 7:00 pm Main Conference Registration

4:00 Event Chairperson’s Opening Remarks

Cindy Crowninshield, RD, LDN, Conference Director, Cambridge Healthtech Institute

4:05 Keynote Introduction

Kevin Brode, Senior Director, Health & Life Sciences, Americas Hitachi Data Systems


Do Network Pharmacologists Need Robot Chemists?

Andrew HopkinsAndrew L. Hopkins, DPhil, FRSC, FSB, Division of Biological Chemistry and Drug Design, College of Life Sciences, University of Dundee


OKTA10 Minute Welcome to the Reception!

Mike Nolte, Regional Sales Manager – East, Okta

Cycle Computing logo
5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

Drop off a business card at the CHI Sales booth for a chance to win 1 of 2 iPads® or 1 of 2 Kindle Fires®!*

*Apple® is not a sponsor or participant in this program


7:00 am Registration and Morning Coffee

8:00 Chairperson’s Opening Remarks

Phillips Kuhl, Co-Founder and President, Cambridge Healthtech Institute

8:05 Keynote Introduction

Sanjay Joshi, CTO, Life Sciences, EMC Isilon


Atul ButteAtul Butte, M.D., Ph.D., Division Chief and Associate Professor, Stanford University School of Medicine; Director, Center for Pediatric Bioinformatics, Lucile Packard Children’s Hospital; Co-founder, Personalis and Numedii


8:55 Benjamin Franklin Award & Laureate Presentation

9:15 Best Practices Award Program

9:45 Coffee Break in the Exhibit Hall with Poster Viewing

Information Management And Collaborative Drug Discovery 

10:50 Chairperson’s Remarks

Yuriy Gankin, Ph.D., CSO, Knowledge Management, GGA Software Services LLC

11:00 Scientific Information as a Business Asset – Driving Productivity at Merck Research Labs Through Novel Approaches to Scientific Information Management

John Koch, Director, Scientific Information Architecture, MRL Informatics, Merck

Biopharma companies often struggle to manage scientific information – study results, analyses and historical record are lost due to poor information management practices and failure to produce information in a way that can be leveraged for future purposes. We will share examples of our strategy for improving information management through a set of capabilities focused on Information Search, Access and Architecture.

11:30 OMOP - A Public Private Partnership between Pharma and the FDA to Study Methods for Observational Studies

Christian Reich, Ph.D., Head of Discovery Informatics, AstraZeneca Pharmaceuticals, Inc.


IDBS(1) 12:00 pm Where Innovation Sparks – Enabling Scientific Collaboration in Fast-Growing, International R&D Companies 

Paul Denny-Gouldson, Ph.D., Vice President, Translational Medicine, IDBS

Scientists are social creatures and most innovation sparks when people come together. Too often a lack of transparency and ‘right-time’ access to real experimental data remains a major barrier to effective internal, external and multinational collaboration. Using scientifically aware, scalable data management systems enables virtual lab meetings to unlock every company’s biggest asset: the innovation power of their own scientists.

Accelrys12:15 pm Solving the Informatics Challenges in Collaborative Network Research

Rob Brown, Ph.D., Senior Director, Life Sciences Research, Accelrys Inc

As discovery organizations move rapidly towards a collaborative network model for research, research IT organizations are presented with significant challenges in supporting their scientists and the external partners. We will present software solutions that can help  solve the problems of tech transfer and collaborative data exchange and present case studies on the use of these solutions from both the pharma/biotech and CRO point of view.

OpenEye_Vertical 12:30 Luncheon Presentation: Tools for Toolmakers, 10 Years of Open Innovation at OpenEye

Robert Tolbert, Ph.D., Senior Vice President, Development, OpenEye Scientific Software

1:40 Chairperson’s Remarks

Yuriy Gankin, Ph.D., CSO, Knowledge Management, GGA Software Services LLC

1:45 Collaborative Discovery: The eTRIKS Approach

Ian Dix, Ph.D., Director Analytics, Information and Knowledge Engineering, R&D Information, AstraZeneca

Yike Guo, Professor, Computing, Imperial College London

Novel Approaches To Drug Discovery 

2:15 Deuterium Modification as a New Branch of Medicinal Chemistry to Develop Novel, Highly Differentiated Drugs

Julie Fields Liu, Ph.D., Director, Research Management, Concert Pharmaceuticals, Inc.

Schrodinger 2:45 Making the Molecules that Matter: The Integrated Approach to Discovery

John Conway, Vice President, Scientific Informatics & Services, Schrodinger
Matt Wessel, Senior Principal Scientist, Schrodinger

The key elements that drive success in drug discovery are improved science, knowledge acquisition, coherent goals leading to rapid decision making, and the ability to collaborate across sites and organizations. At Schrӧdinger, we are building a platform that -- for the first time -- truly enables these elements, and more.  Here, we will outline our vision, describe a success story which exemplifies the vision, and detail how Schrӧdinger will deliver this platform.

3:15 Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 Cataloging Gene Clusters of Bacterial Secondary Metabolism to Enable Drug Discovery

Daniel Udwary, Ph.D., Assistant Professor, Biomedical and Pharmaceutical Sciences, University of Rhode Island

Natural products produced by microbes have been a plentiful source of medicinal compounds for decades, though few have made it to the clinic in recent years. To attempt to identify new sources, we have completed construction of a database that catalogs natural product biosynthetic pathways from all available completed bacterial genome sequences. We are now using this data to identify potentially useful pathways and chemistry, and to explore overlooked organisms with strong biosynthetic potential.” to the end.

4:15 Knowledge Mining in Genome-Scale Protein-Interaction Networks to Understand Drug Resistance

Nagasuma Chandra, Ph.D., Associate Professor, Biochemistry, Indian Institute of Science Department of Biochemistry, Indian Institute of Science

Drug resistance is posing to be a major problem for anti-infective therapy. Using large-scale informatics, an integrated network model that considers known functional, structural and expression information in drug-exposed mycobacterial cells (that cause tuberculosis) has been used to identify potential molecular pathways which the bacterium could be using to trigger resistance to drugs.

4:45 Data and Knowledge Management in the Pharma Environment 

Vishal Rosha, Senior Scientist, BioProcess Research & Development, Novartis Pharma AG

As the technology is growing day by day and a more scientific approach is required. “Sound Science,” as required by the US FDA, suggests gaining more knowledge about the process, which requires more information and leads to more data needed, there is strong belief that the impact of data management concepts and the effort of translation data into information and knowledge are underestimated. The huge amount of data which is generated during the process has to be translated into information and knowledge. In this presentation we identify the gaps of current data/knowledge management concepts. An assessment was performed to demonstrate from which source the related unit operation receives data and to which unit operation it feeds back. In addition, an evaluation was performed to identify the gaps of established concepts and methods which support the translation of data into information and knowledge.

5:15 Best of Show Awards Reception in the Exhibit Hall

6:15 Exhibit Hall Closes

Thursday, April 11

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

Integrating Clinical Information into Drug Discovery 

8:45 Chairperson’s Opening Remarks

Mathukumalli Vidyasagar, Ph.D., Cecil & Ida Green Chair in Systems Biology Science; Head, Bioengineering Department, University of Texas at Dallas 

8:50 The Challenges in Integrating Information During the Discovery of Biomarkers in Cancer Patients Treated with Chemotherapy: A Pharmacology and Oncology Perspective

Federico Innocenti, M.D., Ph.D., Associate Professor, University of North Carolina at Chapel Hill; Associate Director , Institute for Pharmacogenomics and Individualized Therapy

Genomic studies for discovering biomarkers of outcome of patients treated with chemotherapy are quite advanced. However, we face the interpretative difficulty in connecting the dots among clinical data, genomic information (both of the host and the tumor), and functional annotation of genomic regions. This presentation will provide an oncology and pharmacology perspective of the contemporary challenges of integrative analyses that could (and should) aid the discovery of clinically useful markers for enrichment of responsive populations during drug development, as well as for improving patient management at the bed side.

9:20 Integrating Molecular and Clinical Data to Expedite Translation in Computational Drug Repurposing

Joel Dudley, Ph.D., Director, Biomedical Informatics; Assistant Professor, Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine

Although drug repurposing approaches that leverage approved therapies can potentially expedite the drug development process by leveraging existing drug safety data, establishing efficacy for alternative indications can remain just as challenging as in novel drug development. Because many patients are prescribed approved therapies for their primary indications, there is a wealth of clinical data captured in electronic medical record (EMR) systems that could potentially inform on the system-wide physiological and pathophysiological effects of the approved therapies in humans. In this talk I will discuss efforts to integrate public gene expression data with clinical data captured from EMR systems to expedite translation in computational drug repurposing.

Elsevier 9:50 Managing Information Challenges with Elsevier Life Science Solutions  

Shuhag Ghosh, Vice President, Global Marketing, Elsevier Life Science Solutions

From increasing discoverability to making sense of ever-growing data sets to leveraging new data sources, Life Sciences organizations face challenges in making more informed and effective decisions based on a changing landscape. Elsevier Life Science Solutions is a suite of interoperable domain-specific decision support tools built from our understanding of and commitment to Life Sciences. This suite is designed to enhance how organizations make decisions and to power information flows across discovery, pre-clinical, clinical and post-market domains, for end-to-end success. The potential to leverage customized taxonomies, newly mined content sources and internal data in the suite changes how organizations interact with information to conduct R&D.

10:20 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced

10:45 Plenary Keynote Panel Chairperson’s Remarks

Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World

10:50 Plenary Keynote Panel Introduction

Yury Rozenman, Head of BT for Life Sciences, BT Global Services

Niven R. Narain, President & CTO, Berg Pharma


11:05 The Life Sciences CIO Panel

Remy Evard, CIO, Novartis Institutes for BioMedical Research
Martin Leach, Ph.D., Vice President, R&D IT, Biogen Idec
Andrea T. Norris, Director, Center for Information Technology (CIT) and Chief Information Officer, NIH
Gunaretnam (Guna) Rajagopal, Ph.D., VP & CIO - R&D IT, Research, Bioinformatics & External Innovation, Janssen Pharmaceuticals
Cris Ross, Chief Information Officer, Mayo Clinic
Matthew Trunnell, CIO, Broad Institute of MIT and Harvard

12:15 Luncheon in the Exhibit Hall with Poster Viewing

Pharmacogenomics and Personalized Medicine 

1:55 8:45 Chairperson’s Opening Remarks 

Tibor van Rooij, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta; former Director of Bioinformatics, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre  

2:00 The MicroRNA-Drug Resistance Connection: A New Era of Personalized Medicine Using Non-coding RNA Begins

Prasun J. Mishra, Ph.D., Earl Stadtman Investigator Candidate, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Cumulative evidence now suggests that specific miRNAs and genetic variations interfering with miRNA function (miRNA polymorphisms) are involved in the prognosis and progression of a variety of diseases and can serve as biomarkers to predict drug response. Detection of prognostic-miRNAs and miRNA polymorphisms can potentially improve diagnosis, treatment and prognosis in patients and has profound implications in the fields of pharmacogenomics and personalized medicine.

2:30 Discovery of Candidate Biomarkers of Anti-Cancer Drug Sensitivity by High-Throughput Screening of 1,000 Cell Lines

Cyril H. Benes, Ph.D., Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center

In order to translate into cancer care the genomic characterization of cancers, there is a need to understand how variations in genome influence therapeutic responses and which genome variants might constitute good targets. We use a collection of 1,000 genetically characterized tumor cell lines to define molecular determinant of drug sensitivity in vitro. Strikingly, this approach captures essentially all genotype-drug sensitivity associations leveraged in the clinic to date and identifies a large number of novel correlates as candidate biomarkers for the development and application of cancer therapeutics.

3:00 Beyond ENCODE: Placing Long Non-Coding RNA Genes into Regulatory Networks for Therapeutics

Leonard Lipovich, Ph.D., Assistant Professor, Center for Molecular Medicine and Genetics, Wayne State University

In 2012, the ENCODE (Encyclopedia of DNA Elements) Consortium revealed an abundance of long non-coding RNA (lncRNA) genes in the human genome. We analyzed the transcriptome of three human systems - two cancers (breast cancer and melanoma) and the in-vivo human epileptic brain - and validated lncRNA functions by reverse genetic tools. Our results demonstrate that certain primate-specific lncRNAs, antisense to protein-coding genes, directly and specifically regulate those genes. We present a computational model which places these non-conserved lncRNAs into therapeutically targetable disease networks.

3:30 Interactive Medical Decision Trees: Using Up-To-Date Genomics and Information Echnology to Bring Personalized Care to Regional Populations

Tibor van Rooij, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta; former Director of Bioinformatics, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre

4:00 Conference Adjourns

Download Brochure | Pre-Conference Workshops 

View 2016 Photos & Videos  

View 2016 Brochure
View 2016 Brochure
Platinum Sponsors


Cycle Computing logo small

DDN Storage  

Elsevier R&D Solutions


 IBM Logo Illumnia logo  

Intel Logo  

Precision for Medicine


 Seven Bridges Genomics

View All Sponsors

Official Media Partner

Official PR Partner

View All Media Partners

Conference CD

CD iconOrder the 2015 event proceedings - now available on CD

Complimentary Downloads

View white papers, listen to podcasts, and more!

  • Making the World's Knowledge Computable
  • Bioinformatics in the Cloud
  • The Application of Text Analytics to Drug Safety Surveillance

Related Event

 Medical Informatics World Related